The Psychiatric Disease Pipeline: A Strategic Review
Decision Resources
July 22, 2009 27 Pages - SKU: DECR2406399
|
|
Numbers tell the story in psychiatric disease drug development: almost 300 recognized indications,
28% 12-month prevalence that yields large patient populations, strong 7.5% annual sales growth in
recent years, sustained franchise sales, tolerance for use of multiple drugs within a drug class, and
a clinical pipeline of more than 150 agents. Given the heterogeneity of the patient populations in the
psychiatric disease sector, unmet need and commercial opportunity are high. We explore ways in
which companies are using strategic differentiation and novel targets to overcome challenges and tap
sales potential.
Scope
- 2008 market: 2008 sales; leading drug classes; market-leading companies; commercial
position of leading agents.
- Psychiatric disease pipeline: number of agents in development; disease focus; active
companies; profi les of GSK and AZ; mechanisms of action; company type; phase analysis;
novel formulations versus reformulations.
- Psychiatric diseases focused on in this report: schizophrenia; depression; anxiety;
addiction; attention-defi cit/hyperactivity disorder (ADHD); cognitive impairment
associated with schizophrenia (CIAS).
- Opportunities in psychiatric diseases: unmet needs of current treatments; treatmentresistant
depression; bipolar depression; CIAS; line extensions.
- Challenges in psychiatric diseases
Please note, the PDF e-mail from publisher version of this report is for a global site license.
|
- Executive Summary
- Strategic Considerations
- Stakeholder Implications
- Introduction
- The Psychiatric Disease Pipeline by the Numbers
- Companies Developing Psychiatric Disease Agents
- GlaxoSmithKline
- AstraZeneca
- Opportunities and Challenges in the Psychiatric Disease Market
- Important Market Opportunities for Psychiatric Diseases
- High Unmet Need for Treatment-Resistant and Bipolar Depression
- Cognitive Impairment Associated with Schizophrenia
- Challenges Facing Companies with Emerging Psychiatric Agents
- Increased Treatment by PCPs Challenges Emerging Therapy Uptake
- Reimbursement Issues Loom Large for Existing and New Agents Alike
- Outlook: Strategies for Developers in a Challenging Sector
- Current Market Statistics
- Strategies for Emerging Agents
- Tables
- 1. Psychiatric Disease Descriptions
- 2. Drug Classes Commonly Prescribed to Treat Psychiatric Disease
- 3. Unmet Needs in Psychiatric Disease
- 4. GlaxoSmithKline’s Psychiatric Pipeline
- 5. AstraZeneca’s Psychiatric Pipeline
- 6. Agents in Development for the Treatment of Cognitive Impairment Associated
- with Schizophrenia
- 7. Top-Selling Psychiatric Drugs, 2008
- Figures
- 1. The Psychiatric Pipeline, NMEs vs. Reformulations
- 2. The Psychiatric Pipeline, by Target
- 3. The Psychiatric Pipeline, by Disease
- 4. The Psychiatric Pipeline, by Phase of Development
- 5. Leading Psychiatric Pipelines, by Company
- 6. Psychiatric Pipeline Development Activity, by Company Size
- 7. GlaxoSmithKline’s Psychiatric Drug Sales, 2003-2008
- 8; Market Share of Psychiatric Drug Classes, 2008
- 9. Psychiatric Market Growth, 2003-2008
Share this report
Other tasks Related Markets Behavioral Health Reports Free Alert Me service Receive bi-weekly email alerts on new market research Sign Up Today!
|
